---
ticker: "THNR"
name: "Amplify Weight Loss Drug & Treatment ETF"
url: "https://etf.net/etf/THNR"
grade: "C"
score: 43
graded_at: "2026-10-12"
category: "Pharma & Therapeutics"
category_rank: "7 of 9"
methodology: "https://etf.net/methodology"
---

# THNR: Amplify Weight Loss Drug & Treatment ETF

Grade **C**, Score 43 of 100. Rank 7 of 9 in Pharma & Therapeutics.

Graded Oct 12, 2026.

## Grade pillars

| Pillar | Score | Category rank |
| --- | --- | --- |
| Cost | 41 | 5 of 9 |
| Mission | 65 | 5 of 6 |
| Risk | 35 | 7 of 9 |
| Tradability | 17 | 9 of 9 |
| Holdings | 65 | 4 of 9 |
| Durability | 18 | 9 of 9 |

## Top holdings

The fund holds 22 positions. These are the largest 22, by weight.

| # | Ticker | Name | Weight |
| --- | --- | --- | --- |
| 1 | LLY | Eli Lilly & Co | 10.60% |
| 2 | NVO | Novo Nordisk A/S | 8.82% |
| 3 | AMGN | Amgen Inc | 5.86% |
| 4 | ABBV | AbbVie Inc | 5.75% |
| 5 | PFE | Pfizer Inc | 5.51% |
| 6 | ROP.SW | Roche Holding AG | 5.44% |
| 7 | GILD | Gilead Sciences Inc | 5.42% |
| 8 | 1093.HK | CSPC Pharmaceutical Group Ltd | 5.37% |
| 9 | AZN | AstraZeneca PLC | 5.33% |
| 10 | MRK | Merck & Co Inc | 5.25% |
| 11 | REGN | Regeneron Pharmaceuticals Inc | 5.16% |
| 12 | 1801.HK | Innovent Biologics Inc | 5.12% |
| 13 | 4519.T | Chugai Pharmaceutical Co Ltd | 4.73% |
| 14 | VKTX | Viking Therapeutics Inc | 4.60% |
| 15 | ARWR | Arrowhead Pharmaceuticals Inc | 3.83% |
| 16 | 128940.KS | Hanmi Pharm Co Ltd | 3.50% |
| 17 | ZEAL.CO | Zealand Pharma A/S | 3.47% |
| 18 | GPCR | Structure Therapeutics Inc | 2.60% |
| 19 | 1276.HK | Jiangsu Hengrui Pharmaceuticals Co Ltd | 2.29% |
| 20 | KLRA | Kailera Therapeutics Inc | 1.00% |
| 21 | AGPXX | Invesco Government & Agency Portfolio 12/31/2031 | 0.26% |
| 22 | — | Cash & Other | 0.08% |

Source: etf.net, https://etf.net/etf/THNR. Please cite the page URL.